Biggest, richest, strongest, frothiest, riskiest; no matter what superlatives you want to apply, the biotech initial public offering (IPO) boom of 2018 was record breaking. In early December, Moderna Therapeutics’ US$604 million IPO — the largest ever for a venture-backed US biotech company — propelled the total capital raised in biotech IPOs during the year past the $8 billion threshold for the first time in the history of the sector… Para acessar a publicação na íntegra clique aqui Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 18 | JANUARY 2019 |…
FDA approves landmark tissue-agnostic cancer drug
The FDA granted accelerated approval to Loxo Oncology and Bayer’s larotrectinib for patients with solid tumours that have neurotrophic receptor tyrosine kinase (NTRK) gene fusions. Larotrectinib is the first drug to be developed entirely for a tissue-agnostic cancer indication that doesn’t depend on where the cancer originated… Para acessar a publicação na íntegra clique aqui Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 18 | JANUARY 2019 | 7…